Literature DB >> 1687206

Taxol: a new and effective anti-cancer drug.

W J Slichenmyer1, D D Von Hoff.   

Abstract

Taxol is a new anti-cancer drug that is a natural product derived from the bark of the Pacific Yew tree. The drug promotes polymerization and stabilization of tubulin to microtubules and interferes with the mitotic spindle. Clinical trials indicate that taxol is effective in the treatment of patients with refractory ovarian cancer, breast cancer, malignant melanoma and probably other solid tumors. Toxicities include anaphylactoid reactions, leukopenia, peripheral neuropathy and oropharyngeal mucositis. Increased supplies of the drug are required to support further phase II and III testing.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687206

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  29 in total

1.  Paclitaxel-loaded poly(n-butylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer.

Authors:  Fei Ren; Ruda Chen; Ying Wang; Yabin Sun; Yaodong Jiang; Guofeng Li
Journal:  Pharm Res       Date:  2010-12-24       Impact factor: 4.200

2.  Physalin B not only inhibits the ubiquitin-proteasome pathway but also induces incomplete autophagic response in human colon cancer cells in vitro.

Authors:  Yi-ming Ma; Wei Han; Jia Li; Li-hong Hu; Yu-bo Zhou
Journal:  Acta Pharmacol Sin       Date:  2015-03-23       Impact factor: 6.150

3.  Molecular characterization and expression analysis of a gene encoding for farnesyl diphosphate synthase from Euphorbia pekinensis Rupr.

Authors:  Xiaoying Cao; Ting Yin; Qian Miao; Changgen Li; Xiuyun Ju; Yong Sun; Jihong Jiang
Journal:  Mol Biol Rep       Date:  2011-05-26       Impact factor: 2.316

4.  Editorial for Cancer Virtual Issue.

Authors:  Benjamin E Blass
Journal:  ACS Med Chem Lett       Date:  2017-12-14       Impact factor: 4.345

5.  From taxuspine x to structurally simplified taxanes with remarkable p-glycoprotein inhibitory activity.

Authors:  Daniele Castagnolo; Lorenzo Contemori; Giorgio Maccari; Stanislava I Avramova; Annalisa Neri; Gianpietro Sgaragli; Maurizio Botta
Journal:  ACS Med Chem Lett       Date:  2010-07-15       Impact factor: 4.345

6.  Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells.

Authors:  Cheng Jin; Ling Bai; Hong Wu; Wenjie Song; Guozhen Guo; Kefeng Dou
Journal:  Pharm Res       Date:  2009-04-21       Impact factor: 4.200

7.  Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro.

Authors:  T C Chou; G M Otter; F M Sirotnak
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

8.  Demethoxycurcumin Suppresses Human Brain Glioblastoma Multiforme GBM 8401 Cell Xenograft Tumor in Nude Mice In Vivo.

Authors:  Yi-Ping Huang; Yi-Shih Ma; Chao-Lin Kuo; Ching-Lung Liao; Po-Yuan Chen; Shu-Fen Peng; Fei-Ting Hsu; Kuang-Chi Lai
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

Review 9.  Breast cancer: Muscarinic receptors as new targets for tumor therapy.

Authors:  Alejandro Español; Agustina Salem; Yamila Sanchez; María Elena Sales
Journal:  World J Clin Oncol       Date:  2021-06-24

10.  Deep sequencing reveals transcriptome re-programming of Taxus × media cells to the elicitation with methyl jasmonate.

Authors:  Guiling Sun; Yanfang Yang; Fuliang Xie; Jian-Fan Wen; Jianqiang Wu; Iain W Wilson; Qi Tang; Hongwei Liu; Deyou Qiu
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.